trending Market Intelligence /marketintelligence/en/news-insights/trending/WqlZINOFSA2jSwW7eN4izg2 content esgSubNav
In This List

Another proxy firm backs CytRx reverse stock split plan

Video

S&P Capital IQ Pro | Powering Your Edge

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Another proxy firm backs CytRx reverse stock split plan

Institutional Shareholder Services Inc. recommended that CytRx Corp. shareholders vote in favor of the company's proposed reverse stock split at the upcoming Oct. 17 meeting.

The proxy advisory firm was echoing the same advice from Glass Lewis & Co.

The biopharmaceutical company is seeking shareholder approval to implement a 1-for-6 reverse stock split of both its authorized common and preferred stock in an attempt to regain compliance with Nasdaq's $1 minimum bid price requirement to maintain listing on the exchange.